Additionally, a PARP inhibitor such as olaparib (Lynparza®) upregulates PD-L1 expression primarily through GSK3β inactivation [46], indicating that PARP inhibitors render cancer cells more resistant against T-cell-mediated cell death [46]. Here, PARP1 is linked to cancer.